Information  X 
Enter a valid email address

Byotrol PLC (BYOT)

  Print          Annual reports

Tuesday 13 October, 2020

Byotrol PLC


RNS Number : 9358B
Byotrol PLC
13 October 2020




13 October 2020



Byotrol plc





Byotrol plc (AIM: BYOT), the specialist infection prevention and control company, announces that it has today published its audited annual report and accounts for the year ended 31 March 2020 (the "Report"), which is available on its website at The Report includes an unqualified audit opinion.


The notice of Annual General Meeting (to include proposals to create positive distributable reserves for the Company in order to provide the ability to pay dividends if and when appropriate) will be posted as soon as practical. Following shareholder consultation, no proposals will be put forward regarding share consolidation.





Byotrol plc 

David Traynor - Chief Executive Officer

Nic Hellyer - Chief Financial Officer    01925 742 000



Geoff Nash/Kate Bannatyne - Corporate Finance    020 7220 0500

Richard Chambers - ECM


Flagstaff Strategic and Investor Communications

Tim Thompson/Andrea Seymour/Fergus Mellon                             020 7129 1474

[email protected]




Notes to Editors:


Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the Healthcare, Industrial, Food and Consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.


Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.


Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone.


For more information, please go to

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t